Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 6, 2001, Pages 683-690

  Inglis, A M L ^a   Miller, A K ^a   Culkin, K T ^a   Finnerty, D ^a   Patterson, S D ^a   Jorkasky, D K ^a   Freed, M I ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; NORETHINDRONE; OXIDOREDUCTASES, N-DEMETHYLATING; PLACEBOS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035008177     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010456     Document Type: Article

References (39)

1. The triumvirate: βcell, muscle, liver: A collusion responsible for NIDDM
2. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview
3. Role of insulin resistance in human disease (syndrome X): An expanded definition
4. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
5. Thiazolidinediones are novel insulin-sensitizing agents
6. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorγ(PPARγ)
7. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
8. The synthesis of BRL 49653 - A novel and potent antihyperglycaemic agent
9. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ
10. Chronic administration of rosiglitazone does not alter the pharmacokinetics of digoxin
11. Lack of pharmacokinetic drug interaction between rosiglitazone and metformin
12. Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine
13. Coadministration of rosiglitazone and acarbose (A): Lack of a clinically relevant pharmacokinetic drug interaction
14. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics
15. Update: Clinically significant cytochrome P-450 drug interactions
16. Effect of troglitazone on urinary excretion of cortisol and 6-β-hydroxycortisol
17. Effect of troglitazone on terfenadine pharmacokinetics when dosed 4 hours apart
18. Effect of troglitazone on terfenadine pharmacokinetics
19. Potential interaction of troglitazone and cyclosporine
20. Troglitazone in type II diabetes mellitus
21. Recent advances: The cytochrome P450 enzymes
22. High prevalence of comorbid conditions in type 2 diabetics (DM2): UK MediPlus
23. Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent
24. Pharmacotherapeutic case studies in endocrinology
25. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
26. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
27. Systemic exposure to rosiglitazone is unaltered by food
28. A randomized trial of three oral contraceptives: Comparison of bleeding patterns by contraceptive types and steroid levels
29. Menstrual impact of contraception
30. Oral contraceptives and cycle control: A critical review of the literature
31. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive
32. Oral contraceptive steroids - Pharmacological issues of interest to the prescribing physician
33. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women
34. Pharmacokinetic drug interactions with oral contraceptives
35. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids
36. The effect of rifampicin on norethisterone pharmacokinetics
37. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes
38. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus